Literature DB >> 34403361

ZFP91 disturbs metabolic fitness and antitumor activity of tumor-infiltrating T cells.

Feixiang Wang1, Yuerong Zhang1, Xiaoyan Yu1, Xiao-Lu Teng1, Rui Ding1, Zhilin Hu1, Aiting Wang1, Zhengting Wang2, Youqiong Ye1, Qiang Zou1.   

Abstract

Proper metabolic activities facilitate T cell expansion and antitumor function; however, the mechanisms underlying disruption of the T cell metabolic program and function in the tumor microenvironment (TME) remain elusive. Here, we show a zinc finger protein 91-governed (ZFP91-governed) mechanism that disrupts the metabolic pathway and antitumor activity of tumor-infiltrating T cells. Single-cell RNA-Seq revealed that impairments in T cell proliferation and activation correlated with ZFP91 in tissue samples from patients with colorectal cancer. T cell-specific deletion of Zfp91 in mice led to enhanced T cell proliferation and potentiated T cell antitumor function. Loss of ZFP91 increased mammalian target of rapamycin complex 1 (mTORC1) activity to drive T cell glycolysis. Mechanistically, T cell antigen receptor-dependent (TCR-dependent) ZFP91 cytosolic translocation promoted protein phosphatase 2A (PP2A) complex assembly, thereby restricting mTORC1-mediated metabolic reprogramming. Our results demonstrate that ZFP91 perturbs T cell metabolic and functional states in the TME and suggest that targeting ZFP91 may improve the efficacy of cancer immunotherapy.

Entities:  

Keywords:  Immunology; Immunotherapy; Metabolism; T cells

Mesh:

Substances:

Year:  2021        PMID: 34403361      PMCID: PMC8483753          DOI: 10.1172/JCI144318

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Cancer: Live screening of immunotherapy targets.

Authors:  Katie Kingwell
Journal:  Nat Rev Drug Discov       Date:  2014-03-21       Impact factor: 84.694

Review 2.  The spectrum of T cell metabolism in health and disease.

Authors:  Glenn R Bantug; Lorenzo Galluzzi; Guido Kroemer; Christoph Hess
Journal:  Nat Rev Immunol       Date:  2017-09-25       Impact factor: 53.106

3.  Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells.

Authors:  Sema Kurtulus; Asaf Madi; Giulia Escobar; Max Klapholz; Jackson Nyman; Elena Christian; Mathias Pawlak; Danielle Dionne; Junrong Xia; Orit Rozenblatt-Rosen; Vijay K Kuchroo; Aviv Regev; Ana C Anderson
Journal:  Immunity       Date:  2019-01-08       Impact factor: 31.745

Review 4.  Targeting the tumor microenvironment and T cell metabolism for effective cancer immunotherapy.

Authors:  Helen Carrasco Hope; Robert J Salmond
Journal:  Eur J Immunol       Date:  2019-07-09       Impact factor: 5.532

Review 5.  T cell metabolic fitness in antitumor immunity.

Authors:  Peter J Siska; Jeffrey C Rathmell
Journal:  Trends Immunol       Date:  2015-03-12       Impact factor: 16.687

6.  Identification of a novel human gene, ZFP91, involved in acute myelogenous leukemia.

Authors:  Motoko Unoki; Junichi Okutsu; Yusuke Nakamura
Journal:  Int J Oncol       Date:  2003-06       Impact factor: 5.650

Review 7.  Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy.

Authors:  Dayana B Rivadeneira; Greg M Delgoffe
Journal:  Clin Cancer Res       Date:  2018-01-31       Impact factor: 12.531

8.  ECD promotes gastric cancer metastasis by blocking E3 ligase ZFP91-mediated hnRNP F ubiquitination and degradation.

Authors:  Song-Hui Xu; Song Zhu; Yanjie Wang; Jin-Zhou Huang; Min Chen; Qing-Xia Wu; Yu-Tian He; Guang-Rong Yan
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

9.  Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade.

Authors:  Winson S Ho; Herui Wang; Dominic Maggio; John S Kovach; Qi Zhang; Qi Song; Francesco M Marincola; John D Heiss; Mark R Gilbert; Rongze Lu; Zhengping Zhuang
Journal:  Nat Commun       Date:  2018-05-29       Impact factor: 14.919

10.  Phosphatase PP2A is requisite for the function of regulatory T cells.

Authors:  Sokratis A Apostolidis; Noé Rodríguez-Rodríguez; Abel Suárez-Fueyo; Nikolina Dioufa; Esra Ozcan; José C Crispín; Maria G Tsokos; George C Tsokos
Journal:  Nat Immunol       Date:  2016-03-14       Impact factor: 25.606

View more
  3 in total

1.  Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.

Authors:  Wenchao Wu; Geoffrey M Nelson; Raphael Koch; Katherine A Donovan; Radosław P Nowak; Tayla B Heavican-Foral; Ajit J Nirmal; Huiyun Liu; Lei Yang; Jessica Duffy; Foster Powers; Kristen E Stevenson; Marcus Kenneth Jones; Samuel Y Ng; Gongwei Wu; Salvia Jain; Ran Xu; Sam Amaka; Christopher Trevisani; Nicholas L Donaldson; Patrick R Hagner; Laurence de Leval; Philippe Gaulard; Javeed Iqbal; Anjan Thakurta; Eric S Fischer; Karen Adelman; David M Weinstock
Journal:  Blood       Date:  2022-03-31       Impact factor: 25.476

2.  SENP7 senses oxidative stress to sustain metabolic fitness and antitumor functions of CD8+ T cells.

Authors:  Zhongqiu Wu; Haiyan Huang; Qiaoqiao Han; Zhilin Hu; Xiao-Lu Teng; Rui Ding; Youqiong Ye; Xiaoyan Yu; Ren Zhao; Zhengting Wang; Qiang Zou
Journal:  J Clin Invest       Date:  2022-04-01       Impact factor: 14.808

Review 3.  Mitochondria dysfunction in CD8+ T cells as an important contributing factor for cancer development and a potential target for cancer treatment: a review.

Authors:  Lu Zhang; Wen Zhang; Ziye Li; Shumeng Lin; Tiansheng Zheng; Bingjie Hao; Yaqin Hou; Yanfei Zhang; Kai Wang; Chenge Qin; Liduo Yue; Jing Jin; Ming Li; Lihong Fan
Journal:  J Exp Clin Cancer Res       Date:  2022-07-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.